Physician profile
Mary Wang
NPI 1669564811
$17,188.28
in general payments reported to CMS, 2019-2025
31 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,927 · 2020: $2,606 · 2021: $2,644 · 2022: $2,516 · 2023: $2,334 · 2024: $2,296 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,479 · Travel and Lodging: $16.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,478.57 |
| Travel and Lodging | $16.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,121.94 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $2,079.48 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $1,735.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,306.49 | 2019-2025 | Linzess, Creon, Viberzi |
| Glaxosmithkline, LLC. | $1,040.00 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $756.07 | 2019-2022 | |
| Novo Nordisk INC | $699.92 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.77 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $524.34 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $318.70 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $311.97 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $302.94 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $219.83 | 2022-2023 | Livalo, Seglentis |
| Vivus LLC | $189.75 | 2019-2024 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $122.66 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $121.89 | 2019-2022 | |
| Abbott Laboratories | $119.56 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $118.31 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $87.65 | 2019-2022 | |
| Pfizer INC. | $82.25 | 2019-2023 | |
| Exact Sciences Corporation | $68.73 | 2024-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $60.37 | 2021-2022 | |
| Allergan, INC. | $57.54 | 2019-2020 | |
| Astellas Pharma US INC | $56.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.19 | 2021 | |
| Scilex Pharmaceuticals INC. | $32.82 | 2019 | |
| Radius Health, INC. | $23.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.77 | 2021 | |
| Esperion Therapeutics, INC. | $18.84 | 2021 | |
| Dexcom, INC. | $14.88 | 2021 | |
| Redhill Biopharma INC. | $14.88 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.